

AMGEN[®]

*Advancing the Science and
Practice of Nephrology*

Amgen (Europe) GmbH
Dammstrasse 23
CH-6300 Zug
Switzerland

www.amgen.com

© 2017 Amgen Inc. All rights reserved.

INVITATION


Calcimimetics EXPERT FORUM 2017

29–30 SEPTEMBER 2017

Hilton Vienna, Vienna, Austria

AMGEN[®]

*Advancing the Science and
Practice of Nephrology*



It is with great pleasure that you are invited to attend the **Calcimimetics Expert Forum** at the Hilton Vienna, Vienna, Austria, on 29–30 September 2017.

This 2-day event will bring together nephrologists from across Europe and presents an opportunity to hear and critically discuss the latest data on calcimimetics. Facilitated by an expert faculty, the comprehensive programme of didactic lectures and practical workshops will provide detailed insights into the latest clinical developments in CKD-MBD, with a particular focus on the use of calcimimetics in patients with the disease, and enable you to discuss the potential implications of recent data with your peers and leading experts in the field.

We look forward to seeing you in Vienna for an interactive and informative meeting.

Friday 29 September

12.00–13.00 *Lunch*

13.00–14.45 **Plenary session (Chair: Pieter Evenepoel, Belgium)**

Welcome and introduction to Day 1

Bruno Fouqueray, Amgen

Past, present and future: the continuing challenge of CKD-MBD

John Cunningham, UK

Overview of calcimimetics and their clinical use

Jordi Bover, Spain

Panel discussion

Session faculty

14.45–15.15 *Coffee break*

15.15–16.15 **Plenary session**

The benefit–risk profile of etelcalcetide

Bruno Fouqueray, Amgen

16.15–16.45 *Coffee break*

16.45–18.05 **Workshop rotation 1**

Delegates break into two groups and attend one of the following two workshop sessions:

Treating patients with CKD-MBD

David Wheeler, UK together with Amgen

Etelcalcetide: from clinical trial data to real-world experience

Marc Vervloet, The Netherlands together with Amgen

18.05–18.10 **Plenary session**

Day 1 summary

Bruno Fouqueray, Amgen

19.30 *Dinner*

Saturday 30 September

09.00–10.55 **Plenary session (Chair: John Cunningham, UK)**

Introduction to Day 2

Bruno Fouqueray, Amgen

New insights into the role of FGF23 in CKD-MBD and beyond

Marc Vervloet, The Netherlands

Bone strength and fracture risk: current concepts in CKD-MBD

Pieter Evenepoel, Belgium

Potential impact of updated CKD-MBD guidelines on cardiovascular outcomes

David Wheeler, UK

Panel discussion

Session faculty

10.55–11.20 *Coffee break*

11.20–12.40 **Workshop rotation 2**

Delegates break into two groups and attend one of the following two workshop sessions:

Treating patients with CKD-MBD

David Wheeler, UK together with Amgen

Etelcalcetide: from clinical trial data to real-world experience

Marc Vervloet, The Netherlands together with Amgen

12.40–12.50 **Plenary session**

Closing remarks

Bruno Fouqueray, Amgen

12.50–13.50 *Lunch and departures*